ARQ 092

Drug Profile

ARQ 092

Alternative Names: ARQ-092

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule; National Human Genome Research Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proteus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Growth disorders; Proteus syndrome
  • Phase I Solid tumours
  • Preclinical Congenital heart defects; Sickle cell anaemia

Most Recent Events

  • 01 May 2017 Phase-I/II clinical trials in Growth disorders (PIK3CA-Related Overgrowth Spectrum) (In children, In adolescents, In adults, In the elderly) in Italy (PO) (NCT03094832)
  • 01 May 2017 Phase-I/II clinical trials in Proteus syndrome (In children, In adolescents, In adults, In the elderly) in Italy (PO) (NCT03094832)
  • 05 Apr 2017 ArQule plans a phase I/II trial for Proteus syndrome, Growth disorders and PIK3CA-related overgrowth spectrum (PROS) (In children, In adolescents, In adults, In the elderly) in Italy in the second quarter of 2017 (ArQule's form 10-K, filed in March 2017) (NCT03094832)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top